Kosan Biosciences' P2P Acquisition

Kosan Biosciences raised a round of funding on April 13, 2001. Investors include Bristol-Myers Squibb.

is developing two new classes of anticancer agents: heat shock protein 90 (Hsp90) inhibitors and epothilones. Hsp90 inhibitors target multiple pathways involved in cancer cell growth and survival and …

Articles about Kosan Biosciences' P2P Acquisition: